A double blind, randomised, placebo controlled, multi centre study to assess the efficacy and safety of adjunctive zonisamide in myoclonic seizures associated with idiopathic generalised epilepsy.

Phase 3

• Conditions: Epilepsy; Neurological - Epilepsy

• Registration Number: ACTRN12608000097347
• Lead Sponsor: Eisai Ltd.

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2008-02-20
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Stopped early
• Sex: All
• Target Recruitment: 110

Inclusion Criteria

myoclonic seizures

Exclusion Criteria

other type of seizures

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
decrease of seizure frequency[a seizure diary will be used to collect information on frequency of Seizures. A diary will be collected from 8 weeks prior to the study until after 16 weeks of active therpay.]

Secondary Outcome Measures

Name	Time	Method
safety - blood samples will be taken and assessed for safty Laboratory values.[At screening and final visit (after 16 weeks of active therapy)]